Patent Issued for Substituted piperazines as KRAS G12C inhibitors (USPTO 12083121).

A patent has been issued to Amgen Inc. for substituted piperazines as KRAS G12C inhibitors. KRAS gene mutations are common in various types of cancer, including pancreatic cancer, lung adenocarcinoma, and colorectal cancer. The compounds described in the patent can be used to inhibit KRAS G12C activity and treat cancer. The patent provides information on the chemical structures of the compounds and their pharmaceutical formulations. This patent may be of interest to researchers studying cancer treatments and biopharmaceutical companies in the healthcare industry. [Extracted from the article]